Technology for licensing

At Monash University we are recognised for our success in developing new products and services with our commercial partners. We are leaders in commercialising inventions and developing intellectual property within a university environment.

Licensing intellectual property

We regularly license intellectual property to existing companies. This is the most common form of commercialisation. For some innovations, we form spinout companies and facilitate this process through seed funding.

Monash often undertakes research contracts or consultancies together with licensing agreements. These arrangements can help to develop the invention and fast track the commercialisation process.

Current technologies for licensing

Anti-infectives

Monash researchers have developed novel lipopeptide antibiotics to target Gram-negative superbugs, promising to be less apoptopic than polymyxins and with a longer half-life.

Cell Shearer

Monash researchers have developed a novel method for rapidly, sensitively, accurately and quantitatively measuring the mechanical properties of individual red blood cells (RBCs) without physical contact.

Computed tomographic x-ray velocimetry

Monash researchers led by Dr Andreas Fouras have developed a novel computed tomographic X-ray velocimetry imaging technique that can examine and diagnose diseased organs within a living body.

Drying-free ceramic casting method

Monash researchers led by Professor Huanting Wang have developed a method for shape forming of a ceramic green body that eliminates the conventional drying step.

Ectopic pregnancy treatment

Ectopic pregnancies can be resolved safely using a method that requires no invasive surgery.

Gel-form graphene

Monash researchers led by Dr Dan Li have developed a novel method for converting natural graphite into highly porous graphene film for advanced applications.

Graphene oxide reinforced cement

Monash researchers, led by Dr Wenhui Duan, have discovered a novel method for reinforcing concrete construction materials.

Energy Management in Wireless Sensor Networks

Monash researchers have discovered a way to prevent energy failure in wireless sensor networks.

Lung ventilation device

Monash researchers have developed a custom-designed ventilator to provide breathing assistance to the lungs of small animals for use in imaging experiments. This technology can be used clinically for pre-term infants and adults.

MicroCube technology vaccine platform

The MicroCube is uniquely suited to the delivery of vaccines in a safe, stable and effective way. The versatility of this technology makes it an ideal platform for the treatment of HIV, cancer and other disease.

Next generation surgical robot

Monash researchers have developed an improved surgical robotic arm capable of pivoting spherically about a remote centre of motion (RCM).

Novel antibodies directed to c-Met

Cancer treatment can now be more specific and effective with the generation of three classes of antibodies by Monash researchers, each with a specific role in targeting the c-Met receptor.

Novel methods to isolate human cardiomyocytes

Monash researchers have developed a new way to enrich and purify cardiomyocyte cells from human pluripotent stem cell populations.

Platelet aggregation device

Blood flow affects the growth of clots in the bloodstream, which can lead to serious medical conditions such as strokes. Researchers can understand this process better by replicating it precisely in the laboratory, allowing us to develop new treatments for abnormal blood clotting.

Predicting radiation sensitivity in cancer patients

Over 100,000 people in Australia will be diagnosed with cancer in 2011. Monash researchers have developed a way to identify those sensitive to radiation, which will allow doctors to provide more accurate dosages during radiation treatment.

Targeted and genome wide analysis of 3’ UTR dynamics

Monash University molecular biologist, Dr Traude Bilharz has developed a simple and accurate method to measure the poly(A)-tail length of RNA molecules such as mRNA.

Contact us

We welcome inquiries from prospective commercial partners from all sectors. Contact our team if you need further information.